Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 180

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 180
---
 of the Business Combination. In addition, the terms of any equity or debt
instruments that may be issued in the future could contain prohibitions or restrictions on the ability of the combined company to pay
dividends on its common stock. The payment of any cash dividends subsequent to the consummation of the Business Combination will be within
the discretion of the Board. In addition, the FutureTech Board is not currently contemplating and does not anticipate declaring stock
dividends in the foreseeable future nor is it currently expected that the FutureTech Board will declare any dividends.

Longevity

Summary Historical Market
Price

Historical market
price data for Longevity is not provided because Longevity is currently a privately-held company. As such, Longevity Common Shares are
not currently listed on a public stock exchange and are not publicly traded. Therefore, no market data is available for Longevity.

| 79 |

<div align='center'>UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL INFORMATION</div>

Defined terms
included below have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus, except as set forth in
the following sentence.

The unaudited
pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X, as amended by the
final rule, Release No. 33-10786 and presents the combination of the historical financial information of FutureTech, Longevity, Aegeria
and Cerevast adjusted to give effect to the Business Combination and other related events contemplated by the Transaction Agreements (“Other
Related Events”).

The unaudited
pro forma condensed combined balance sheet as of September 30, 2024 combines the historical unaudited condensed balance sheet of FutureTech
as of September 30, 2024, the historical unaudited condensed balance sheet of Longevity as of September 30, 2024, the historical unaudited
condensed balance sheet of Aegeria as of September 30, 2024 and the historical unaudited condensed balance sheet of Cerevast as of September
30, 2024 on a pro forma basis as if the Business Combination and Other Related Events, summarized below, had been consummated on September
30, 2024.

The unaudited
pro forma condensed combined statements of operations for the nine months ended September 30, 2024 and the year ended December 31, 2023